Global Nuclear Medicine/ Radio Pharmaceuticals Market 2025 – 2034

<p><strong>Reports Description</strong> <p><strong>Global Nuclear Medicine/ Radio Pharmaceuticals </strong><strong>Market </strong>was valued at<strong> USD 8,016.1 Million </strong>in 2025 and is expected to reach <strong>USD 15,895.1 Million </strong>by 2034, at a CAGR of <strong>7.90% </strong>during the forecast period 2025 - 2034.</p> <p>The nuclear medicine/radiopharmaceuticals are radioisotopes, which are bound to biological molecules and able to target specific organs, tissues, or cells in the human body. These radioactive drugs are used for the diagnosis and in the therapy of the various diseases.</p></p> <h3>Nuclear Medicine/ Radio Pharmaceuticals Market Growth Factors</h3> <p><strong>Increasing Incidences and Prevalence of the Target Conditions</strong></p> <p>Nuclear medicine/radiopharmaceuticals are used to diagnose the various diseases. The patient will inhale, swallow, or be injected with a radiopharmaceutical. This is a radioactive material. After taking the substance, the patient will normally lie down on a table while a camera takes pictures.</p> <p>The growing prevalence of the target conditions across the globe is expected to drive the demand for nuclear medicine/radiopharmaceuticals during the forecast period. For instance, according to the World Health Organization (WHO), in 2023, there were an estimated 24 million new cancer cases and 10.3 million deaths worldwide.</p> <p>Approximately 1 in 5 people develop cancer in their lifetime, with about 1 in 9 men and 1 in 12 women succumbing to the disease.</p> <p>Radiopharmaceuticals are agents used to diagnose certain medical problems or treat certain diseases. They may be given to the patient in several different ways. Furthermore, according to the American Heart Association 2023, the approximately 23.45 million deaths happened due to the cardiovascular diseases in 2023.</p> <p>The growing prevalence of these diseases is projected to drive the growth of the market during the forecast period. Thus, such factors are expected to drive the overall market growth.</p> <h3>New Product Launches in the Nuclear Medicine/Radiopharmaceuticals</h3> <p>The growing investment by the major key players operating in the market in the new product launches and enhancement of the new business operations is expected to drive the consumption of the nuclear medicine/radiopharmaceuticals during the forecast period.</p> <p>The development and advancements in the new targeting molecules, such as prostate-specific membrane antigen (PSMA) ligands for the treatment of prostate cancers and fibroblast activation protein inhibitors (FAPI), are expected to increase the consumption of nuclear medicine and radiopharmaceuticals during the forecast period.</p> <p>For instance, GE Healthcare has launched the Xeleris V, a virtual processing and review solution for nuclear medicine. Together with Smart Subscription and advanced AI applications powered by Edison, we are transforming the way nuclear medicine works.</p> <p>Recently, in January 2024, Lantheus Holdings Inc. made a strategic partnership with Perspective Therapeutics, Inc. Under these agreements, Lantheus obtained an option to exclusively license Perspective’s Pb212-VMT-⍺-NET, a clinical-stage alpha therapy developed for the treatment of neuroendocrine tumors.</p> <p>Thus, growing investment by the major key players in the new product development is expected to drive the demand for the nuclear medicine/radiopharmaceuticals market during the forecast period.</p> <h3>Nuclear Medicine/ Radio Pharmaceuticals Market Restraints</h3> <p><strong>High Cost of the Nuclear Medicine/Radiopharmaceuticals</strong></p> <p>The high cost of the nuclear medicine/radiopharmaceuticals is expected to restrain the overall market growth. The radiopharmaceutical materials are highly expensive compared with other resources employed in the nuclear medicine department.</p> <p>The nuclear medicine/radiopharmaceuticals are composed of Technetium-99m, Iodine-123, Xenon-133, Thallium-201, Indium-111, Iodine-131, and Iridium-19. The cost of these materials is very high and increases with increasing raw material and processing costs.</p> <p>Radiopharmaceuticals used in nuclear medicine are made of various radioactive elements and a non-radioactive element such as Tc-99m, technetium, thallium, gallium, iodine, and xenon. These elements are very rare in the earth materials.</p> <p>The cost of this material is very high and increases exponentially due to growing inflation. Thus, such factors are increasing the overall cost of the nuclear medicine and restraining the overall market growth.</p> <p><strong>Supply chain limitations and logistical challenges</strong></p> <p>Supply chain limitations associated with the nuclear medicine is mainly restraining the market growth. The key players operating in the market are facing tremendous challenges due to the supply chain limitations and logistical challenges.</p> <p>The heavy dependence of the China and Others developing countries for raw material is creating the supply chain disturbances is mainly restraining the market growth. Furthermore, shortage of skilled labours and medical personnel across the globe due to high remuneration of skilled labours is creating difficulties in the market growth.</p> <h3>Global Nuclear Medicine/ Radio Pharmaceuticals Market Segmentation Analysis</h3> <p>Global Nuclear Medicine/ Radio Pharmaceuticals Market is segmented by type, by modality, by application, by end user and by region. By type, the market is segmented into diagnostics, therapeutics and biochemistry research.</p> <p>Among all of these, diagnostics type segment dominated the market and is expected to keep its dominance during the forecast period owing to the growing demand for the diagnostic types across the large patient base and increasing research and development across the diagnostic techniques.</p> <p>Furthermore, growing number of nuclear medicine procedure across the globe is expected to create lucrative opportunities for the market during the forecast period. The increasing research and development across the Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography is expected to fuel the demand for the diagnostic technologies, thereby driving the overall market growth.</p> <p>Therapeutics segment is expected to grow at fastest CAGR during the forecast period. Radionuclide therapy is unique characteristics of the radioactive materials (radioisotopes), which are used for therapeutic irradiation of cells and/or organs.</p> <p>By modality, the market is segmented into SPECT, PET, alpha-emitters, beta-emitters, and brachytherapy. Among all of these, the SPECT segment dominated the market in 2024 and is expected to keep its dominance during the forecast period.</p> <p>A SPECT scan is a type of imaging test that uses a radioactive substance and a special camera to create the 3D pictures. Various factors, such as the increasing prevalence of cardiovascular diseases, rising adoption of cardiovascular OCT scanning, and growing public awareness about the OCT scanning and heart disease, are mainly driving the market growth of this segment during the forecast period.</p> <p>The growing usage of the single-photon emission computed tomography systems for the identification of attacks, tremors, and Alzheimer's disease, among other conditions.</p> <p>By application, the market is segmented into urology, oncology, cardiology, neurology, thyroid, and others. The urology segment dominated the market in 2024 and is expected to keep its dominance during the forecast period owing to the increasing prevalence of urological diseases such as prostate cancer and increasing demand for novel products for diagnosis and treatment.</p> <p>Many countries, such as Japan, India, China, Germany, France, Russia, Italy, and Spain, are mainly driving the market growth of this segment due to increasing cases of prostate cancer due to the rising male population and changed lifestyle of people.</p> <p>The oncology segment is expected to grow at the fastest CAGR during the forecast period. Various factors, such as the increasing consumption of alcohol and tobacco, are increasing the burden of oncology, increasing incidences of cancers, and growing initiatives pertaining to the adoption of oncology diagnostics and oncology treatment across the globe, thereby boosting the growth of the global oncology market.</p> <p>Furthermore, growing spending on the awareness of the cancer is expected to drive the market growth of this segment during the forecast period. For instance, according to the International Agency for Research on Cancer (IARC), there were more than 21.3 million new cancer cases estimated in the 2023 and is expected to increase the number exponentially across the globe.</p> <p>By end user, the hospitals segment held highest market share in 2024 and is expected to keep its dominance during the forecast period. The growing number of the construction of new hospitals across the globe due to growing investment by the private and government key players across the globe.</p> <p>Most of the therapeutic nuclear medicine are mainly conducted in the hospitals. The increasing number of supportive policies in the developing countries to establish the new hospitals is expected to create lucrative opportunities for this segment during the forecast period.</p> <p><strong>Report Scope</strong></p> <table> <tbody> <tr> <td><strong>Feature of the Report</strong></td> <td><strong>Details</strong></td> </tr> <tr> <td>Market Size in 2025</td> <td>USD 8,016.1 Million</td> </tr> <tr> <td>Projected Market Size in 2034</td> <td>USD 15,895.1 Million</td> </tr> <tr> <td>Market Size in 2024</td> <td>USD 7,429.2 Million</td> </tr> <tr> <td>CAGR Growth Rate</td> <td>7.90% CAGR</td> </tr> <tr> <td>Base Year</td> <td>2024</td> </tr> <tr> <td>Forecast Period</td> <td>2025-2034</td> </tr> <tr> <td>Key Segment</td> <td>By Type, Modality, Application, End User and Region</td> </tr> <tr> <td>Report Coverage</td> <td>Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends</td> </tr> <tr> <td>Regional Scope</td> <td>North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America</td> </tr> <tr> <td>Buying Options</td> <td>Request tailored purchasing options to fulfil your requirements for research.</td> </tr> </tbody> </table> <h3>Global Nuclear Medicine/ Radio Pharmaceuticals Market Regional Analysis</h3> <p>By region, the <a href="https://custommarketinsights.com/press-releases/nuclear-medicine-radiopharmaceuticals-market-size/">Nuclear Medicine/ Radio Pharmaceuticals market</a> is segmented into North America, Asia Pacific, Europe, the Middle East & Africa, and Latin America. Among all of these, the North America region held highest market share in 2024 and is expected to keep its dominance during the forecast period. Key countries such as U.S., Canada and Mexico are mainly driving the market growth of this region.</p> <p>The North America’s dominance is mainly driven by the growing adoption of the advanced technologies and presence of the major key players in the region and increasing use of innovative therapeutic radiopharmaceuticals. Furthermore, growing prevalence of the various chronic cancer conditions is significantly boosting the market growth.</p> <p>U.S. held major market share in the North America region owing to the increasing number of the cardiac patients in the region and growing adoption of the precise imaging technologies equipped with the various technologies such as PET and SPECT.</p> <p>Asia Pacific region is expected to grow at fastest CAGR during the forecast period owing to the growing number of hospitals and clinics which has led to high demand for products, driven by a rise in patient visits for disease diagnosis and treatment.</p> <p>Key countries such as China, India, Japan, ASEAN and South Korea are mainly driving the market growth of this region. China held highest market share in 2024 and is expected to keep its dominance during the forecast period owing to the growing prevalence of the chronic diseases across the region.</p> <p><strong>Global Nuclear Medicine/ Radio Pharmaceuticals Market Recent Developments</strong></p> <ul> <li>In February 2023, <a href="https://www.gehealthcare.in/">GE Healthcare</a> launched its 600 and 800 Series nuclear medicine systems due to a potential risk of injury to patients. The new product launch is classified as a Class I recall by the U.S. Food and Drug Administration (FDA), the most serious type of recall.</li> </ul> <ul> <li>In June 2024, the GE healthcare expanded its technology portfolio with the addition of a MINItrace Magni, designed to be a small footprint cyclotron for reliable, in-house production of commercial PET tracers and radiometals. This new product portfolio is designed to evolve and help meet growing healthcare system demands across care areas.</li> </ul> <p>List of the prominent players in the <strong>Nuclear Medicine/ Radio Pharmaceuticals Market</strong>:</p> <ul> <li>GE Healthcare</li> <li>The Australian Nuclear Science and Technology Organization</li> <li>Eckert and Ziegler</li> <li>The Institute for Radioelements</li> <li>Eczacibasi-Monrol</li> <li>Nordion Inc.</li> <li>Bracco Imaging S.P.A</li> <li>NTP Radioisotopes SOC Ltd.</li> <li>Lantheus Medical Imaging Inc.</li> <li>Jubilant Life Sciences Ltd</li> <li>Others</li> </ul> <p>The <strong>Nuclear Medicine/ Radio Pharmaceuticals Market</strong> is segmented as follows:</p> <p><strong>By Type</strong></p> <ul> <li>Diagnostics</li> <li>Therapeutics</li> <li>Biochemistry Research</li> </ul> <p><strong>By Modality</strong></p> <ul> <li>SPECT</li> <li>PET</li> <li>Alpha-emitters</li> <li>Beta-emitters</li> <li>Brachytherapy</li> </ul> <p><strong>By Application</strong></p> <ul> <li>Oncology</li> <li>Urology</li> <li>Cardiology</li> <li>Neurology</li> <li>Thyroid</li> <li>Others</li> </ul> <p><strong>By End User</strong></p> <ul> <li>Hospitals and Diagnostic Centers</li> <li>Research Institutes</li> </ul> <p><strong>Regional Coverage:</strong></p> <p><strong>North America</strong></p> <ul> <li>U.S.</li> <li>Canada</li> <li>Mexico</li> <li>Rest of North America</li> </ul> <p><strong>Europe</strong></p> <ul> <li>Germany</li> <li>France</li> <li>U.K.</li> <li>Russia</li> <li>Italy</li> <li>Spain</li> <li>Netherlands</li> <li>Rest of Europe</li> </ul> <p><strong>Asia Pacific</strong></p> <ul> <li>China</li> <li>Japan</li> <li>India</li> <li>New Zealand</li> <li>Australia</li> <li>South Korea</li> <li>Taiwan</li> <li>Rest of Asia Pacific</li> </ul> <p><strong>The Middle East & Africa </strong></p> <ul> <li>Saudi Arabia</li> <li>UAE</li> <li>Egypt</li> <li>Kuwait</li> <li>South Africa</li> <li>Rest of the Middle East & Africa</li> </ul> <p><strong>Latin America</strong></p> <ul> <li>Brazil</li> <li>Argentina</li> <li>Rest of Latin America</li> </ul>